• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Horizon Technology Finance Provides $40 Million Loan Facility to Hyperfine

    3/23/26 8:00:00 AM ET
    $HRZN
    $HYPR
    Finance: Consumer Services
    Finance
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HRZN alert in real time by email

    Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon") (the "Company"), an affiliate of Monroe Capital, today announced it has provided a $40 million loan facility to Hyperfine, Inc. (NASDAQ:HYPR) ("Hyperfine"), with an initial funding of $15 million at closing, and up to $25 million available to support future commercial growth.

    Hyperfine is a publicly traded health technology company that has developed and is commercializing the Swoop® System, the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system. Cleared for brain imaging in patients of all ages, the Swoop® System brings brain imaging directly to the patient in various care settings including the ICU, emergency departments, smaller community hospitals, and neurology offices. The system delivers diagnostic quality images and can be safely and easily operated at the point of care without the need for a specialized MRI technician.

    "Hyperfine has built a truly differentiated technology platform that is expanding access to brain imaging in settings where conventional MRI is not accessible, practical, affordable nor readily available," said Paul Seitz, Chief Investment Officer of Horizon. "With strong clinical and economic evidence, a growing commercial opportunity with expanding sites of care, and a second-generation system that delivers diagnostic quality images, we are excited to support Hyperfine's continued growth and the broader adoption of point-of-care neuroimaging."

    "Horizon has a deep understanding of the medtech space and the unique needs of companies at our stage of commercial growth," said Maria Sainz, Chief Executive Officer and President of Hyperfine. "This facility provides us with the capital to accelerate the commercial expansion of our Swoop® System across hospital and office settings as well as globally as we expand the reach and access of MRI for acute and chronic brain conditions providing high clinical and economic value to patients, clinicians and providers."

    About Horizon Technology Finance

    Horizon Technology Finance Corporation (NASDAQ:HRZN), externally managed by Horizon Technology Finance Management LLC, an affiliate of Monroe Capital, is a leading specialty finance company that provides capital in the form of secured loans to venture capital and private equity-backed companies and publicly traded companies in the technology, life science, healthcare information and services, and sustainability industries. The investment objective of Horizon is to maximize its investment portfolio's return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. Horizon is headquartered in Farmington, Connecticut, with a regional office in Pleasanton, California, and investment professionals located throughout the U.S. Monroe Capital is a premier asset management firm specializing in private credit markets across various strategies, including direct lending, technology finance, venture debt, opportunistic, structured credit, real estate and equity. To learn more, please visit horizontechfinance.com.

    About Hyperfine

    Hyperfine, Inc. (NASDAQ:HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit HyperfineMRI.com.

    Forward-Looking Statements

    Statements included herein may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in Horizon's filings with the Securities and Exchange Commission. Horizon undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260323418520/en/

    Investor Relations:

    ICR

    Garrett Edson

    ir@horizontechfinance.com

    (860) 284-6450

    Media Relations:

    ICR

    Chris Gillick

    HorizonPR@icrinc.com

    (646) 677-1819

    Get the next $HRZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HRZN
    $HYPR

    CompanyDatePrice TargetRatingAnalyst
    Hyperfine Inc.
    $HYPR
    4/29/2026$2.00Buy
    BTIG Research
    Horizon Technology Finance Corporation
    $HRZN
    3/5/2026$5.00Underperform → Mkt Perform
    Keefe Bruyette
    Horizon Technology Finance Corporation
    $HRZN
    5/13/2025$7.00Neutral
    B. Riley Securities
    Horizon Technology Finance Corporation
    $HRZN
    4/30/2025$6.50Neutral → Sell
    Compass Point
    Horizon Technology Finance Corporation
    $HRZN
    12/17/2024$8.25Sell → Neutral
    Compass Point
    Horizon Technology Finance Corporation
    $HRZN
    2/28/2024Buy → Neutral
    Ladenburg Thalmann
    Horizon Technology Finance Corporation
    $HRZN
    1/8/2024$11.00Neutral → Sell
    B. Riley Securities
    Horizon Technology Finance Corporation
    $HRZN
    10/17/2023$10.00Neutral → Sell
    Compass Point
    More analyst ratings

    $HRZN
    $HYPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Hyperfine with a new price target

    BTIG Research initiated coverage of Hyperfine with a rating of Buy and set a new price target of $2.00

    4/29/26 9:31:47 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Horizon Technology Finance upgraded by Keefe Bruyette with a new price target

    Keefe Bruyette upgraded Horizon Technology Finance from Underperform to Mkt Perform and set a new price target of $5.00

    3/5/26 2:01:21 PM ET
    $HRZN
    Finance: Consumer Services
    Finance

    B. Riley Securities resumed coverage on Horizon Technology Finance with a new price target

    B. Riley Securities resumed coverage of Horizon Technology Finance with a rating of Neutral and set a new price target of $7.00

    5/13/25 10:04:46 AM ET
    $HRZN
    Finance: Consumer Services
    Finance

    $HRZN
    $HYPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hyperfine to Join Russell 2000® and Russell 3000® Indexes

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system— today announced that Hyperfine is expected to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the June 2026 Russell Reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 22, 2026. Hyperfine's inclusion will become effective after the U.S. market close on June 26, 2026. The June reconstitution of the Russell US indexes captures up to the 4,000 largest U.S. stocks as of April 30, ranking them by total mark

    5/26/26 8:15:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine Announces Presentation of Results from the PRIME Study Showing Portable MRI Substantially Reduces Time to Imaging in Emergency Departments

    Prospective randomized ED study shows rapid bedside imaging, detection of critical neurological findings, and potential workflow efficiency benefits with portable MRI Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the presentation of results of the PRIME (Portable Rapid Imaging for Medical Emergencies) study at the Society for Academic Emergency Medicine (SAEM) 2026 Annual Meeting. PRIME is a single-center, prospective, randomized controlled trial designed to evaluate the role of portable MRI in neurological emergencies i

    5/22/26 8:15:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine, Inc. Reports First Quarter 2026 Financial Results

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced first quarter 2026 financial results and provided a business update. "Our execution in Q1 was strong. We delivered our second-highest revenue quarter to date with over 80% year-over-year revenue growth, driven by our accelerating commercial engine. We believe the international regulatory clearances we secured, the clinical data we released to the neurology and stroke communities, and the continued momentum in our office and hospital businesses all indicate p

    5/12/26 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HRZN
    $HYPR
    SEC Filings

    View All

    SEC Form EFFECT filed by Hyperfine Inc.

    EFFECT - Hyperfine, Inc. (0001833769) (Filer)

    5/22/26 12:15:17 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Hyperfine, Inc. (0001833769) (Filer)

    5/21/26 4:11:58 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Horizon Technology Finance Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Horizon Technology Finance Corp (0001487428) (Filer)

    5/14/26 4:32:25 PM ET
    $HRZN
    Finance: Consumer Services
    Finance

    $HRZN
    $HYPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Balkin Michael bought $170,600 worth of shares (20,000 units at $8.53) (SEC Form 4)

    4 - Horizon Technology Finance Corp (0001487428) (Issuer)

    12/17/24 1:23:10 PM ET
    $HRZN
    Finance: Consumer Services
    Finance

    President Michaud Gerald A. bought $74,519 worth of shares (8,000 units at $9.31), increasing direct ownership by 5% to 169,309 units (SEC Form 4)

    4 - Horizon Technology Finance Corp (0001487428) (Issuer)

    12/2/24 11:38:46 AM ET
    $HRZN
    Finance: Consumer Services
    Finance

    Director Savage Joseph J bought $88,150 worth of shares (9,500 units at $9.28), increasing direct ownership by 19% to 59,500 units (SEC Form 4)

    4 - Horizon Technology Finance Corp (0001487428) (Issuer)

    11/14/24 4:23:08 PM ET
    $HRZN
    Finance: Consumer Services
    Finance

    $HRZN
    $HYPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Wolterman Dan

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    6/4/26 7:12:27 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CFO and CAO Hale Brett sold $9,978 worth of shares (6,047 units at $1.65), decreasing direct ownership by 1.00% to 599,765 units (SEC Form 4)

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    5/27/26 4:26:36 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Operating Officer Teisseyre Thomas sold $9,978 worth of shares (6,047 units at $1.65), decreasing direct ownership by 0.88% to 678,601 units (SEC Form 4) (withholding obligation)

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    5/27/26 4:26:16 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HRZN
    $HYPR
    Leadership Updates

    Live Leadership Updates

    View All

    Hyperfine to Join Russell 2000® and Russell 3000® Indexes

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system— today announced that Hyperfine is expected to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the June 2026 Russell Reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 22, 2026. Hyperfine's inclusion will become effective after the U.S. market close on June 26, 2026. The June reconstitution of the Russell US indexes captures up to the 4,000 largest U.S. stocks as of April 30, ranking them by total mark

    5/26/26 8:15:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Seth Appel Joins Roth as Head of ATM & Equity Alternatives Banking and Co-Chief Investment Officer of RoHo Capital Opportunities Fund

    NEWPORT BEACH, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- via IBN – Roth Capital Partners ("Roth"), www.roth.com, is pleased to announce the strategic appointment of Seth Appel as Head of ATM & Equity Alternatives Banking. Mr. Appel brings over 30 years of capital markets experience and will focus on expanding Roth's capabilities in equity capital markets, with particular expertise in helping growth companies raise capital efficiently and creatively. In connection with his appointment, Mr. Appel will also serve as Co-Chief Investment Officer of RoHo Capital Opportunities Fund, a newly formed joint venture between Horizon Technology Finance Corporation (NASDAQ:HRZN), an affiliate of Monroe

    4/16/26 11:54:01 AM ET
    $HRZN
    Finance: Consumer Services
    Finance

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    $HRZN
    $HYPR
    Financials

    Live finance-specific insights

    View All

    Hyperfine, Inc. Reports First Quarter 2026 Financial Results

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced first quarter 2026 financial results and provided a business update. "Our execution in Q1 was strong. We delivered our second-highest revenue quarter to date with over 80% year-over-year revenue growth, driven by our accelerating commercial engine. We believe the international regulatory clearances we secured, the clinical data we released to the neurology and stroke communities, and the continued momentum in our office and hospital businesses all indicate p

    5/12/26 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Horizon Technology Finance Announces First Quarter 2026 Financial Results

    - Successfully Completed Merger with Monroe Capital Corporation in April - - First Quarter 2026 Net Investment Income per Share of $0.19; NAV per Share of $6.98 - - Debt Portfolio Yield of 15.2% - - Ends Quarter with Committed Backlog of $180 Million - Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon" or the "Company"), an affiliate of Monroe Capital, today announced its financial results for the first quarter ended March 31, 2026. First Quarter 2026 and Recent Highlights In April, successfully completed merger with Monroe Capital Corporation ("MRCC"), receiving approximately $141.1 million in cash and issuing 20,370,645 shares of common stock in the aggregate to

    5/5/26 4:15:00 PM ET
    $HRZN
    Finance: Consumer Services
    Finance

    Hyperfine, Inc. to Announce First Quarter 2026 Financial Results on May 12, 2026

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the first quarter 2026 on Tuesday, May 12, 2026. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. For more information

    4/28/26 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HRZN
    $HYPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Hyperfine Inc.

    SC 13G - Hyperfine, Inc. (0001833769) (Subject)

    2/13/24 5:06:19 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

    SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

    2/14/23 4:07:09 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

    SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

    12/20/22 4:22:37 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care